These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34698447)

  • 1. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
    Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
    Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
    Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
    Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Kim RY; Li Y; Marmarelis ME; Vachani A
    Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
    BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
    Lee CW; Murray N; Anderson H; Rao SC; Bishop W
    Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
    Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
    Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
    ESMO Open; 2022 Dec; 7(6):100644. PubMed ID: 36463732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N
    Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
    Petrelli F; Ardito R; Conti B; Coinu A; Cabiddu M; Ghilardi M; Borgonovo K; Barni S; Ghidini A
    Respir Med; 2018 Aug; 141():72-80. PubMed ID: 30053976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    Van den Bossche J; De Laere M; Deschepper K; Germonpré P; Valcke Y; Lamont J; Stein B; Van Camp K; Germonpré C; Nijs G; Roelant E; Anguille S; Lion E; Berneman Z
    PLoS One; 2024; 19(7):e0307204. PubMed ID: 39008481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.